Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Accu-Chek

- PMLiVE

Mylan, Biocon’s Herceptin biosimilar launched in US

Bad news for Roche as its ageing blockbuster continues to lose ground

- PMLiVE

Roche’s Soliris rival satralizumab scores in phase 3 study

Therapy has been filed in US and Europe with decisions expected in 2020

AstraZeneca AZ

AstraZeneca eyes early 2020 FDA verdict on Imfinzi in SCLC

Will go head-to-head with rival Roche's Tecentriq if approved

- PMLiVE

Roche’s Tecentriq/Avastin combo improves survival in liver cancer

First regimen to achieve improved overall survival in ten years

- PMLiVE

Roche scores FDA priority review for risdiplam in SMA

Potential rival to Novartis’ Zolgensma and Biogen’s Spinraza

Roche Basel Switzerland

Roche agrees $1.4bn takeover of fibrosis specialist Promedior

Portfolio includes phase 2 candidate with FDA breakthrough status

- PMLiVE

FDA advisors say no to empagliflozin in type 1 diabetes

Approval of Boehringer, Lilly-partnered drug expansion looks unlikely

Roche Basel Switzerland

Roche’s Spinraza, Zolgensma rival risdiplam hits the mark in SMA

Will file for approval in US and other world markets before end of the year

- PMLiVE

Sanofi reveals positive phase 3 results for long-acting insulin Toujeo

Hopes new product can offset continuing decline in franchise

Roche Basel Switzerland

US, EU regulators start review of Roche’s Soliris rival satralizumab

Sets up a possible market clash with Alexion next year

Roche Basel Switzerland

Roche moving closer to approval of Spark takeover; report

Antitrust authorities in both US and UK look likely to end delay

- PMLiVE

Seattle Genetics preps filing next year for oral HER2 drug

Company has positive phase 3 data to support filings

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links